The Disease Spread Product Flavored Clinical Research For The Treatment Of Primary Liver Cancer (Syndrome Of Yin Deifciency Of Liver And Kidney)

Purpose: This subject adoptsThe disease spread product flavored treatment for primaryhepatic carcinoma (syndrome of yin deficiency of liver and kidney) in clinical research. Thestudy of disease of digestive system belongs to the internal medicine of traditional Chinesemedicine research field.Based on the disease spread product side flavored treatment ofprimary hepatic carcinoma (syndrome of yin deficiency of liver and kidney) of damp and hot,Explicit disease spread product clinical efficacy and safety of flavored.Method: All patients were from changchun university of Chinese medicine treatmentarea and affiliated hospital liver spleen and stomach disease outpatient service, And all in linewith the primary liver cancer (syndrome of yin deficiency of liver and kidney) clinicaldiagnosis, And sign the informed consent. This research adopts randomized controlled method,Selected cases were randomly divided into2groups, the treatment group of36patients,thecontrol group of36patients.in the process of clinical observation may lead to sample loss,sothe60cases on the basis of a20%increase in the number of samples. Treatment group giventhe disease spread product side flavored herbal medicinal broth, The control group givencompound cantharis capsules. For4weeks for1course of treatment, Watch a period oftreatment, Signs and symptoms were measured and recorded before and after the treatment,the change of liver function, alpha fetoprotein (AFP), Compare their differences, andstatistical processing and evaluation.Result: Treatment group30cases and control group30cases, according to a total of60patients completed the treatment in this study. Observe the total curative effect, Treatmentgroup and control group total effectiveness90%,80%respectively, which were16.66%,0%,effective73.33%,80%,10%,20%is invalid. To observe the main clinical symptomsimprovement, Treatment group total integral average was24.05+/-6.25, before aftertreatment was11.33+/-3.88; Control group total integral mean value of24.36+/-5.54before treatment, after treatment was14.86+/-3.90. The total curative effect, livermeritorious service is, a tire protein expression, symptom integral, after statistics processing,P <0.05, statistically significant, that is, the treatment group curative effect is better than thecontrol group. And the treatment group before and after treatment symptoms integral contrast, symptoms improved significantly after treatment. All the above are about the bulk productside flavored treatment the disease curative effect is better than that of compound canthariscapsule.Conclusion: The bulk product side flavored treatment of primary hepatic carcinoma (hotand humid intrinsic liver and kidney Yin deficiency syndrome), can obviously relievesymptoms, its definite effect.